Futura Medical PLC Block Listing Six Monthly Return (6972A)
31 Maio 2023 - 3:00AM
UK Regulatory
TIDMFUM
RNS Number : 6972A
Futura Medical PLC
31 May 2023
Block Listing Six Monthly Return
31 May 2023
Futura Medical plc (AIM: FUM), a pharmaceutical company
developing a portfolio of innovative products for sexual health and
pain relief, makes the following update on its block listings,
pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for
Companies. All figures relate to options over Ordinary Shares of
0.2 pence each (Ordinary Shares).
Date: 30 November 2022
Name of applicant: Futura Medical Plc
Name of scheme(s): Unapproved Share Option Scheme
Unapproved Share Incentive Scheme
EMI Share Option Scheme
LTIP Scheme
-----------------------------------------
Period of return: From: 1 December 2022 To: 31 May 2023
----------------------- ---------------- ---- -----------------
Balance of unallotted securities under scheme(s) from previous return: 6,981,779
-----------------------------------------
Plus: The amount by which the block scheme(s) has been increased since the EMI: 1,100,000
date of the last LTIP: 4,444,942
return (if any increase has been applied for):
-----------------------------------------
Less: Number of securities issued/allotted under scheme(s) during period: USOS: nil
EMI: nil
LTIP: nil
-----------------------------------------
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 12,526,721
-----------------------------------------
Number and class of securities originally admitted and the date of USOS Total: 3,882,912
admission 814,424 25 May 2011
1,202,280 8 October 2013
1,466,208 25 May 2017
400,000 30 May 2018
USIS Total: 425,000
425,000 30 November 2018
EMI Total: 8,112,088
1,520,576 25 May 2011
1,467,720 8 October 2013
1,893,792 25 May 2017
790,000 30 May 2018
1,340,000 30 November 2018
1,100,000 2 February 2023
LTIP Total: 4,444,942
4,444,942 2 February 2023
-----------------------------------------
For further information, please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Hollie Vile/ Jonathan Edwards/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Development and
commercialisation strategies are designed to maximise product
differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel
treatment for erectile dysfunction ("ED") through a unique
evaporative mode of action. Futura has previously conducted an
initial Phase 3 study using MED3000 in ED, referred to as "FM57"
which enabled Futura to be granted a CE Mark in 2021. A second
confirmatory Phase 3 clinical study, "FM71" was also conducted to
support Futura's regulatory submission to the FDA with 96 ED
patients and endpoints at 24 weeks, demonstrating that MED3000
presents an effective clinically proven treatment for ED with a
rapid speed of onset and a favourable benefit versus risk profile
ideally suited for an 'Over the Counter' classification.
Eroxon(R) is CE marked in Europe and UKCA marked in the UK as a
clinically proven topical treatment for adult men with erectile
dysfunction under the brand Eroxon(R) with a key claim of "Helps
you get an erection within 10 minutes". Eroxon(R) is the agreed
brand name in certain regions such as the EU whereas MED3000
continues to be the internal code name used by the Company and also
in reference to countries where regulatory approval or commercial
distribution agreements have not yet been achieved.
www.eroxon.com
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLRUVAOROSUVUAR
(END) Dow Jones Newswires
May 31, 2023 02:00 ET (06:00 GMT)
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
